萊美藥業(300006.SZ)擬1.65億元轉讓禾正製藥100%股權予布萊森
格隆匯 2 月 8日丨萊美藥業(300006.SZ)公佈,為進一步聚焦優勢細分領域,公司於2021年2月5日召開的第五屆董事會第十二次會議、第五屆監事會第九次會議分別審議通過了《關於轉讓四川禾正製藥有限責任公司股權的議案》,同意公司與杭州布萊森醫藥科技有限公司(“布萊森”)簽署《股權轉讓協議》,將持有四川禾正製藥有限責任公司(“禾正製藥”、“目標公司”)100%股權(含其全資子公司成都禾正生物科技有限公司(“成都禾正”)、四川萊禾醫藥科技有限公司(“萊禾科技”))以人民幣1.65億元轉讓給布萊森。此次股權轉讓完成後,公司將不再持有禾正製藥(含成都禾正和萊禾科技)股權,禾正製藥(含成都禾正和萊禾科技)將不再納入公司合併報表範圍。
禾正製藥主要從事中藥製劑生產銷售業務,主要產品包括五酯膠囊、抗病毒濃縮丸等,其主營業務不符合公司未來發展戰略規劃。此次股權轉讓交易事項完成後,禾正製藥(含成都禾正和萊禾科技)不再納入公司合併報表範圍,有利於更好地配置公司資源、提高資產運營效率,有利於公司進一步聚焦抗腫瘤、消化道、抗感染等優勢細分領域。此次股權轉讓交易事項預計對公司2021年損益影響金額約為人民幣2853萬元,最終數據將以經審計的財務報吿數據為準,敬請廣大投資者注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.